Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gastroenterology | Hematology | Oncology | Journal

Back to Journal Articles

Treating H. Pylori Bacteria Effective for Gastric Lymphoma

Last Updated: February 25, 2010.

 

Meta-analysis finds remission rate of 77.5 percent in early-stage disease after bacteria eradication

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Eradication of Helicobacter pylori in the stomachs of patients with early-stage gastric lymphoma results in the remission of approximately 75 percent of them, according to a meta-analysis reported in the February issue of Clinical Gastroenterology and Hepatology.

THURSDAY, Feb. 25 (HealthDay News) -- Eradication of Helicobacter pylori in the stomachs of patients with early-stage gastric lymphoma results in the remission of approximately 75 percent of them, according to a meta-analysis reported in the February issue of Clinical Gastroenterology and Hepatology.

Angelo Zullo, M.D., of the Nuovo Regina Margherita Hospital in Rome, and colleagues conducted a pooled analysis of data from 32 studies on 1,408 patients with early-stage gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach to determine remission and relapse rates following therapy to eradicate H. pylori.

The researchers found that the overall MALT lymphoma remission rate was 77.5 percent in the combined cohorts. Remission was higher in Asian than Western patients (84.1 and 73.8 percent, respectively), and higher for patients with stage I lymphoma compared to stage II lymphoma (78.4 and 55.6 percent, respectively). Remission rates also were higher among subjects without the API2-MALT1 translocation chromosomal abnormality than those with the abnormality (78 and 22.2 percent, respectively). The researchers analyzed available long-term follow-up data for 994 subjects and calculated a 7.2 percent lymphoma relapse rate over 3,253 patient-years. In subjects in which both H. pylori infection and lymphoma reoccurred (16.7 percent), re-eradication therapy effectively treated both conditions.

"H. pylori eradication is effective in treating approximately 75 percent of patients with early-stage gastric lymphoma. Long-term follow-up evaluation of these patients is needed to detect early lymphoma relapse or progression," the authors conclude.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2010 HealthDay. All rights reserved.


Previous: Critical Thinking Training Is Key for Perioperative Nurses Next: Annual Colonoscopy Helpful for High-Risk Cancer Group

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.